Pharmaxis Ltd
ASX:PXS.AX
0.03 (AUD) • At close December 7, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Pharmaxis Ltd |
Symbool | PXS.AX |
Munteenheid | AUD |
Prijs | 0.028 |
Beurswaarde | 20,233,192 |
Dividendpercentage | 0% |
52-weken bereik | 0.027 - 0.065 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Gary Jonathan Phillips BPharm, MBA |
Website | https://www.pharmaxis.com.au |
An error occurred while fetching data.
Over Pharmaxis Ltd
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)